Evidence map›Paper›PMID 42595901›Full record

ArticleAnalytical and bioanalytical chemistry2026

Structural insights into antibody-antibody interactions in sandwich ELISA: implications for assay development and performance.

Yue Su, Bo Zhao, Youmi Moon, Yue Fu, Elif Karayusuf, Emily Ressegue, Xiaojiao Xue, Joshua Zylstra, Christine Grimaldi, Bojie Zhang and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yue SuAnalytical and Biological Mass Spectrometry, Regeneron Pharmaceuticals, Inc, 777 Old Saw Mill River Road, Tarrytown, NY, 10591-6706, USA.
Bo ZhaoAnalytical and Biological Mass Spectrometry, Regeneron Pharmaceuticals, Inc, 777 Old Saw Mill River Road, Tarrytown, NY, 10591-6706, USA. bo.zhao@regeneron.com.ORCID http://orcid.org/0000-0002-1882-3182
Youmi MoonProduct Biochemistry, Regeneron Pharmaceuticals, Inc, 777 Old Saw Mill River Road, Tarrytown, NY, 10591-6706, USA.
Yue FuProduct Biochemistry, Regeneron Pharmaceuticals, Inc, 777 Old Saw Mill River Road, Tarrytown, NY, 10591-6706, USA.
Elif KarayusufAssay Development, Regeneron Pharmaceuticals, Inc, 777 Old Saw Mill River Road, Tarrytown, NY, 10591-6706, USA.
Emily RessegueAssay Development, Regeneron Pharmaceuticals, Inc, 777 Old Saw Mill River Road, Tarrytown, NY, 10591-6706, USA.
Xiaojiao XueAssay Development, Regeneron Pharmaceuticals, Inc, 777 Old Saw Mill River Road, Tarrytown, NY, 10591-6706, USA.
Joshua ZylstraAssay Development, Regeneron Pharmaceuticals, Inc, 777 Old Saw Mill River Road, Tarrytown, NY, 10591-6706, USA.
Christine GrimaldiAssay Development, Regeneron Pharmaceuticals, Inc, 777 Old Saw Mill River Road, Tarrytown, NY, 10591-6706, USA.
Bojie ZhangTherapeutic Proteins, Regeneron Pharmaceuticals, Inc, 777 Old Saw Mill River Road, Tarrytown, NY, 10591-6706, USA.
Hui XiaoAnalytical and Biological Mass Spectrometry, Regeneron Pharmaceuticals, Inc, 777 Old Saw Mill River Road, Tarrytown, NY, 10591-6706, USA. hui.xiao@regeneron.com.
Ning LiAnalytical and Biological Mass Spectrometry, Regeneron Pharmaceuticals, Inc, 777 Old Saw Mill River Road, Tarrytown, NY, 10591-6706, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The enzyme-linked immunosorbent assay (ELISA) is a widely utilized immunoassay technique in biopharmaceutical drug development due to its high sensitivity and specificity. Optimizing assay performance necessitates addressing challenges that arise during method development, particularly the selection of compatible monoclonal antibody (mAb) pairs for use as capture and detection antibodies. A common approach to measure human mAb therapeutics in nonclinical studies is to use generic human-specific mAb reagents that specifically recognize human immunoglobulin constant regions. In this study, we investigated the antibody-antibody interactions for a panel of reagent mAbs that bind to distinct epitopes in the constant regions of the human IgG heavy and light chains that may contribute to diminished signal and elevated background in the sandwich ELISA format. Using both in-solution and on-plate characterization methods including hydrogen-deuterium exchange mass spectrometry (HDX-MS), native size exclusion chromatography coupled with mass spectrometry (nSEC-MS), and biolayer interferometry (BLI), we identified signal attenuation as a result of overlapping binding sites, leading to competitive or steric interference that hinders detection antibody binding. Additionally, elevated background signals were attributed to cross-reactivity between capture and detection antibodies. Furthermore, our results also reveal that antibody interactions at distinct epitopes induce different extents of steric hindrance, which significantly impacts the degree of oligomerization within the resulting product complexes. These insights enhance our understanding of the molecular mechanisms affecting assay performance and offer strategies for improving immunoassay design.

Indexed as

Antibody-antibody interactionsEpitope mappingHDX-MSImmunoassay developmentNative SEC-MSSandwich ELISA

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.